Baseline Characteristics of the Patients in the Two Treatment Groups * Placebo
暂无分享,去创建一个
G. Lamas | B. Davis | M. Pfeffer | P. Kowey | J. Rouleau | E. Braunwald | M. Packer | G. Flaker | D. Rutherford | H. Miller | A. Moye
[1] R. Temple,et al. More on the survival and ventricular enlargement trial. , 1993, The New England journal of medicine.
[2] P. Ridker,et al. Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function , 1993, Circulation.
[3] K. Thygesen,et al. Effects of Captopril on Ischemia and Dysfunction of the Left Ventricle After Myocardial Infarction , 1993, Circulation.
[4] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[5] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[6] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[7] P. Ridker. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease , 1992 .
[8] G. Mancia,et al. ACE Inhibition Attenuates Sympathetic Coronary Vasoconstriction in Patients With Coronary Artery Disease , 1992, Circulation.
[9] W. Bussmann,et al. [The angiotensin-converting enzyme inhibitor in the treatment of angina pectoris]. , 1992, Deutsche medizinische Wochenschrift.
[10] M. Pfeffer,et al. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial , 1991 .
[11] C. Lai,et al. [Effects of benazepril, a new ACE inhibitor, in effort angina pectoris]. , 1991, Cardiologia.
[12] N. Rietbrock,et al. Converting Enzyme Inhibition in Coronary Artery Disease: A Randomized, Placebo‐Controlled Trial with Benazepril , 1991, Journal of cardiovascular pharmacology.
[13] J. Laragh,et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.
[14] J. Cleland,et al. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. , 1991, Journal of the American College of Cardiology.
[15] P. Peduzzi,et al. Ten‐Year Incidence of Myocardial Infarction and Prognosis After Infarction: Department of Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery , 1991, Circulation.
[16] A. Marmor,et al. Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study. , 1991, Cardiology.
[17] W. Klein,et al. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. , 1990, Journal of the American College of Cardiology.
[18] A. Richards,et al. Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris. , 1990, The American journal of cardiology.
[19] David Oakes,et al. Prognostic significance of nonfatal myocardial reinfarction , 1990 .
[20] Prognosis and management after a first myocardial infarction. , 1990, The New England journal of medicine.
[21] K. Fox,et al. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. , 1989, British heart journal.
[22] H. Baumgartner,et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.
[23] J. Mimuro,et al. Type 1 plasminogen activator inhibitor. , 1989, Progress in hemostasis and thrombosis.
[24] J. Wittes,et al. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. , 1988, JAMA.
[25] G. Cocco,et al. Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina , 1988, Clinical cardiology.
[26] B. Gersh,et al. Time to first new myocardial infarction in patients with severe angina and three-vessel disease comparing medical and early surgical therapy: a CASS registry study of survival. , 1988, The Journal of thoracic and cardiovascular surgery.
[27] C. Kluft,et al. Plasminogen activator inhibitors. , 1987, Blood.
[28] G. Cocco,et al. Effects of captopril on the physical work capacity of normotensive patients with stable-effort angina pectoris. , 1987, Cardiology.
[29] R. Kleiger,et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. , 1986, The New England journal of medicine.
[30] J. Rouleau,et al. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. , 1985, Circulation.
[31] J. Knoke,et al. Survival after recovery from acute myocardial infarction. Two and five year prognostic indices. , 1979, The American journal of medicine.
[32] W. Kannel,et al. Prognosis after initial myocardial infarction: the Framingham study. , 1979, The American journal of cardiology.
[33] N. Hollenberg,et al. Accentuated vascular and endocrine response to SQ 20881 in hypertension. , 1977, The New England journal of medicine.
[34] A. Vedin,et al. Deaths and non-fatal reinfarctions during two years' follow-up after myocardial infarction. , 2009, Acta medica Scandinavica.
[35] A. Slabý,et al. [Plasma renin activity and ischemic heart disease]. , 1975, Casopis lekaru ceskych.